The goal is established the frequency increase of intraocular pressure (IOP) and endophthalmitis as well as other complications that may occur after intravitreal application of bevacizumab. Subjects and methodology: The study included 45 patients and 75 eyes with exudative form of senile degeneration of macula lutea, who were treated in the General Hospital Prim. Dr. Abdulah Nakas from 2007. and 2010., the patients being aged between 55 and 75 years. The intraocular pres¬sure (IOP) was measured before the application of bevacizumab, and then after 1st, 2nd and 3rd dose, and it was examined by the bio-microscope two days after the application of bevacuzimab. Result: The average age of the patients treated by bevacizumab was 71.27 years (71 years, 3 months, and 7 days); 28 patients were females and 17 were males. The examination by bio-microscope indicates changes at certain number of patients. After first dose of bevacizumab, there were 9 suffu¬sions of the bulbar conjuctiva in the application area. After the second dose, there were 10 of them, while after the third dose of bevacizumab, there were 5 suffusions and 3 cases of inflammation of the anterior eye segment, anterior uveitis. As for the intraocular pressure, there is no statistically significant difference (p>0.05) for any measuring period. Conclusion: Based on the results achieved in the intravitreal application of bevacizumab in treatment of senile degeneration of macula lutea, we can conclude that there is a possibility of infection after intravitreal application of bevacizumab, but it is minimal when working in a sterile environment. Increased intraocular pressure is possible, but not necessarily to happened after the intravitreal application of the drug.
Key words: Bevacizumab, intraocular pressure, endophthalmitis, senile degeneration of macula lutea.
|
